Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 7/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17820036 | 0.91 | ATM (0.46) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17819636 | 0.89 | ATM (0.51) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17819772 | 0.88 | ATM (0.50) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17821066 | 0.88 | ATM (0.48) | ATMPIK3C3PIK3CAPRKDCMTOR | |
| SCHEMBL17821035 | 0.88 | ATM (0.49) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17820212 | 0.88 | ATM (0.49) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17907125 | 0.87 | PIK3C3 (0.48) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17819743 | 0.86 | PIK3C3 (0.48) | ATMPIK3C3PIK3CAPRKDCAKT1 | |
| SCHEMBL17828052 | 0.86 | ATM (0.47) | ATMPIK3C3PIK3CATGFBR1PRKDC | |
| SCHEMBL17820361 | 0.86 | ATM (0.48) | ATMPIK3C3PIK3CAPRKDCAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | ATM 3209/4885PIK3C3 3047/4885PIK3CA 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.